Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US

Simpson KN, Jones WJ, Rajagopalan R, Dietz B

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coronary Disease /epidemiology /etiology; Costs and Cost Analysis; Data Collection; Drug Combinations; HIV Infections /drug therapy /economics /epidemiology; HIV Protease Inhibitors /adverse effects /economics /therapeutic use; Humans; Lopinavir; Male; Markov Chains; Models, Statistical; Pyrimidinones /adverse effects /economics /therapeutic use; Quality of Life; Quality-Adjusted Life Years; Ritonavir /adverse effects /economics /therapeutic use; Survival Analysis; United States /epidemiology; Viral Load

AccessionNumber
22007001472

Date bibliographic record published
27/07/2007